What is aTyr Pharma's stock-based comp?

aTyr Pharma (ATYR) reported stock-based comp of $1.31M in Q1 2026.

How has aTyr Pharma's stock-based comp changed year-over-year?

aTyr Pharma's stock-based comp increased by 11.0% year-over-year, from $1.18M to $1.31M.

What is the long-term trend for aTyr Pharma's stock-based comp?

Over 4 years (2021 to 2025), aTyr Pharma's stock-based comp has grown at a 32.6% compound annual growth rate (CAGR), from $1.61M to $5M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

aTyr Pharma ATYR Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

Merck & Co.MRK

$185M-5.1%

United TherapeuticsUTHR

$33.9M+6.6%

Design Therapeutics, Inc.DSGN

$3.92M+10.9%

CytomX TherapeuticsCTMX

$4.71M+134%

Vor BiopharmaVOR

$8.87M+359%

Other financials

Income statement

See full

Revenue-—

Operating income-$11.4M+27.5%

Net income-$10.8M+27.5%

EPS (diluted)-$0.11+35.3%

Balance sheet

See full

Cash & equivalents$10.0M-3.4%

Total debt$12.3M-9.2%

Total equity$57.9M-22.8%

Total assets$79.7M-18.1%

Cash flow

See full

Operating cash flow-$12.5M+18.8%

CapEx$138.0K—

Free cash flow-$12.7M+17.9%

Valuation

See full

Market cap$54.88M-88.2%

Enterprise value$57.17M—

P/S288.8×—

Profitability

See full

Operating margin-40,856.3%+28,833pp

Net margin-39,009.5%+29,653pp

FCF margin-32,664.7%+4,018pp

Returns & leverage

See full

Return on equity-105.3%+50.6pp

Debt / equity0.2×0.0×

Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is aTyr Pharma's stock-based comp?: aTyr Pharma (ATYR) reported stock-based comp of $1.31M in Q1 2026.
How has aTyr Pharma's stock-based comp changed year-over-year?: aTyr Pharma's stock-based comp increased by 11.0% year-over-year, from $1.18M to $1.31M.
What is the long-term trend for aTyr Pharma's stock-based comp?: Over 4 years (2021 to 2025), aTyr Pharma's stock-based comp has grown at a 32.6% compound annual growth rate (CAGR), from $1.61M to $5M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.